Chromic Chloride label

Chromic Chloride

Chromic Chloride Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Chromic Chloride Injection, USP is indicated for use as a supplement to intravenous solutions given for Total Parenteral Nutrition (TPN). Administration helps to maintain plasma levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

History

There is currently no drug history available for this drug.

Other Information

Chromic Chloride Injection, USP is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). Each mL contains Chromic Chloride Hexahydrate 20.5 mcg, Water for Injection q.s. pH adjusted with Hydrochloric Acid if necessary. It delivers elemental Chromium 4 mcg/mL. The 10 mL vial is a single dose preservative free vial. Discard any unused portion.

Chromic Chloride Manufacturers

  • Chromic Chloride | American Regent, Inc.
    No Recall

    Chromic Chloride | American Regent, Inc.

    Chromic Chloride | American Regent, Inc.

    Chromic Chloride Injection, USP provides 4 mcg chromium/mL. For the metabolically stable adult receiving TPN, the suggested additive dosage level is 10-15 mcg chromium/day. The metabolically stable adult with intestinal fluid loss may require 20 mcg chromium/day, with frequent monitoring of blood levels as a guideline for subsequent administration. For pediatric patients, the suggested additive dosage level is 0.14 to 0.20 mcg/kg/day. Aseptic addition of Chromic Chloride Injection, USP to the TPN solution under a laminar flow hood is recommended. Chromium is physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN.

    Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.